Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen’s Stelara recommended by NICE for Crohn’s disease

Janssen’s Stelara recommended by NICE for Crohn’s disease

22nd June 2017

Janssen's inflammatory disease therapy Stelara has been provisionally approved for routine NHS use as a treatment for Crohn's disease.

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending that the ustekinumab therapy be made available as an option for treating the disease in adults who have had little or no response to existing therapies, or are intolerant to older drugs.

Stelara is a human monoclonal antibody treatment that binds to specific proteins to stop the production of cytokines that cause inflammatory responses in the body, and has already been approved by NICE for the treatment of psoriasis and psoriatic arthritis.

It has been shown to offer quality of life improvements and good tolerability levels among people with Crohn's disease, a condition associated with an unpredictable pattern of remission and relapse.

Professor Carole Longson, director of the health technology evaluation centre at NICE, said: “Ustekinumab provides a convenient and viable option for patients with Crohn's. It is a new way of treating the disease compared to conventional treatment, and can be used where other options have already been tried and stopped working."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801837106-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.